The agent, which just recently received approval from the U.S. Food and Drug Administration (FDA), works differently then traditional molecular imaging agents such as PET scans that are less specific. The new agent is the first to specifically identify the accumulation of amyloid plaques and neuronal tangles that cause cell death in the brain.
“Molecular imaging is already revolutionizing the detection and diagnosis of diseases like Alzheimer’s; and now, it is becoming an indispensable component in the development of exciting new drug therapies, improving patient health,” said Michael Reitermann, president, Molecular Imaging, Siemens Medical Solutions.
